<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555800</url>
  </required_header>
  <id_info>
    <org_study_id>INER</org_study_id>
    <nct_id>NCT02555800</nct_id>
  </id_info>
  <brief_title>Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis</brief_title>
  <official_title>Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Investigación en. Enfermedades Infecciosas, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro de Investigación en. Enfermedades Infecciosas, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal
      antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in
      patients with recurrent respiratory papillomatosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a randomized, double-blind, placebo-controlled study. Children and
      adults will be randomized to receive either 3 dosis of intralesional bevacizumab, cidofovir
      or saline solution. Primary endpoints are the assessment of changes in the annual surgery
      rate and Derkay papilloma severity grading scale; secondary endpoints are changes in the
      Voice Handicap Index and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the annual surgery rate</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in the annual surgery rate before and after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of airway affection measured by the Derkay papilloma severity grading scale</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in the Derkay papilloma severity grading scale before and after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hoarseness severity measured by the Voice Handicap Index</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in the Voice Handicap Index before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-Related Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Recurrent Respiratory Papillomatosis</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cidofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir</intervention_name>
    <description>Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.</description>
    <arm_group_label>Cidofovir</arm_group_label>
    <other_name>Vistide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with recurrent respiratory papillomatosis proven by biopsy.

          -  Patients with 2 or more previous surgeries for papillomatosis

        Exclusion Criteria:

          -  Patients with heart or renal disease

          -  Patients who receive another adjuvant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Reyes-Terán, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Investigación en. Enfermedades Infecciosas, Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuria Ablanedo-Terrazas, M.D.</last_name>
    <phone>+525556667985</phone>
    <email>yuria.ablanedo@cieni.org.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Investigacion en Enfermedades Infecciosas</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Reyes-Teran, M.D.</last_name>
      <phone>+52(55)56667985</phone>
    </contact>
    <contact_backup>
      <last_name>Yuria Ablanedo-Terrazas, M.D.</last_name>
      <phone>+52(55)56667985</phone>
    </contact_backup>
    <investigator>
      <last_name>Gustavo Reyes-Teran, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuria Ablanedo-Terrazas, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arturo Ramírez-García, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Estrada-Camacho, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Tona-Acedo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>September 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro de Investigación en. Enfermedades Infecciosas, Mexico</investigator_affiliation>
    <investigator_full_name>Gustavo Reyes-Teran</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Laryngeal papillomatosis</keyword>
  <keyword>Cidofovir</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Recurrent respiratory papillomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cidofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

